Table 2.
Clinical outcomes in long term versus short term dual antiplatelet therapy (DAPT) after implantation of drug eluting stent stratified by diabetes
| Diabetes (n=3681) | No diabetes (n=7708) | P for interaction | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long DAPT (n=1853) | Short DAPT (n=1828) | HR (95% CI) | P value | τ2 | Long DAPT (n=3848) | Short DAPT (n=3860) | HR (95% CI) | P value | τ2 | |||
| MACE | 62 (3.3) | 58 (3.2) | 1.05 (0.62 to 1.76) | 0.86 | 0.16 | 82 (2.1) | 97 (2.5) | 0.97 (0.67 to 1.39) | 0.85 | 0.06 | 0.33 | |
| All cause death, MI, or stroke | 74 (4.0) | 66 (3.6) | 1.10 (0.79 to 1.54) | 0.58 | 0.00 | 93 (2.4) | 99 (2.6) | 1.02 (0.72 to 1.46) | 0.91 | 0.07 | 0.48 | |
| Cardiac death, MI, or stroke | 69 (3.7) | 59 (3.2) | 1.12 (0.79 to 1.60) | 0.52 | 0.01 | 90 (2.3) | 106 (2.7) | 1.01 (0.68 to 1.49) | 0.97 | 0.11 | 0.16 | |
| All cause death, MI, stroke, or major bleeding | 81 (4.4) | 69 (3.8) | 1.16 (0.83 to 1.60) | 0.39 | 0.01 | 109 (2.8) | 107 (2.8) | 1.12 (0.76 to 1.66) | 0.56 | 0.12 | 0.58 | |
| Cardiac death, MI, stroke, or major bleeding | 81 (4.4) | 71 (3.9) | 1.10 (0.79 to 1.53) | 0.57 | 0.01 | 117 (3.0) | 120 (3.1) | 1.23 (0.77 to 1.96) | 0.38 | 0.22 | 0.46 | |
| All cause death or MI | 68 (3.7) | 59 (3.2) | 1.16 (0.78 to 1.72) | 0.46 | 0.04 | 83 (2.2) | 90 (2.3) | 1.02 (0.71 to 1.47) | 0.91 | 0.07 | 0.39 | |
| Cardiac death or MI | 60 (3.2) | 56 (3.1) | 1.05 (0.65 to 1.69) | 0.85 | 0.11 | 80 (2.1) | 93 (2.4) | 1.08 (0.69 to 1.70) | 0.73 | 0.16 | 0.37 | |
| All cause death | 49 (2.6) | 39 (2.1) | 1.34 (0.87 to 2.06) | 0.19 | 0.02 | 59 (1.5) | 57 (1.5) | 1.05 (0.73 to 1.51) | 0.81 | 0.00 | 0.53 | |
| Cardiac death | 30 (1.6) | 23 (1.3) | 1.29 (0.75 to 2.23) | 0.36 | 0.00 | 37 (1.0) | 35 (0.9) | 1.17 (0.72 to 1.91) | 0.53 | 0.03 | 0.58 | |
| Stroke | 13 (0.7) | 10 (0.5) | 1.29 (0.56 to 2.97) | 0.55 | 0.02 | 15 (0.4) | 16 (0.4) | 0.94 (0.47 to 1.90) | 0.87 | 0.00 | 0.57 | |
| MI | 37 (2.0) | 39 (2.1) | 0.95 (0.58 to 1.54) | 0.82 | 0.03 | 55 (1.4) | 62 (1.6) | 1.15 (0.68 to 1.94) | 0.60 | 0.19 | 0.84 | |
| Definite ST | 4 (0.2) | 11 (0.6) | 0.34 (0.11 to 1.08) | 0.07 | 0.04 | 13 (0.3) | 8 (0.2) | 1.63 (0.67 to 3.97) | 0.28 | 0.02 | 0.04 | |
| Probable ST | 3 (0.2) | 5 (0.3) | 0.59 (0.14 to 2.48) | 0.47 | 0.00 | 4 (0.1) | 4 (0.1) | 0.87 (0.21 to 3.62) | 0.85 | 0.10 | 0.61 | |
| Definite/probable ST | 7 (0.4) | 16 (0.9) | 0.26 (0.09 to 0.80) | 0.02 | 0.47 | 17 (0.4) | 12 (0.3) | 1.42 (0.68 to 2.98) | 0.35 | 0.00 | 0.04 | |
| MI or definite/probable ST | 42 (2.3) | 46 (2.5) | 0.90 (0.55 to 1.46) | 0.66 | 0.06 | 60 (1.6) | 71 (1.8) | 0.94 (0.64 to 1.38) | 0.75 | 0.04 | 0.79 | |
| TVR | 56 (3.0) | 71 (3.9) | 0.82 (0.57 to 1.90) | 0.30 | 0.02 | 107 (2.8) | 115 (3.0) | 0.86 (0.63 to 1.16) | 0.32 | 0.03 | 0.42 | |
| Major or minor bleeding | 38 (2.1) | 21 (1.1) | 1.89 (1.10 to 3.27) | 0.02 | 0.02 | 62 (1.6) | 46 (1.2) | 1.43 (0.96 to 2.11) | 0.08 | 0.01 | 0.37 | |
| Major bleeding | 14 (0.8) | 8 (0.4) | 1.72 (0.72 to 4.10) | 0.22 | 0.00 | 30 (0.8) | 14 (0.4) | 2.56 (1.08 to 6.07) | 0.03 | 0.43 | 0.69 | |
| Minor bleeding | 24 (1.3) | 13 (0.7) | 3.91 (1.24 to 12.40) | 0.02 | 0.87 | 33 (0.9) | 35 (0.9) | 0.82 (0.49 to 1.37) | 0.45 | 0.04 | 0.11 | |
MACE=major adverse cardiac events (cardiac death, myocardial infarction (MI), or definite/probable stent thrombosis (ST)); TVR=target vessel revascularisation.